[1] 蒋宁一, 林岩松, 关海霞, 等.  131I治疗格雷夫斯甲亢指南(2013版)[J]. 标记免疫分析与临床, 2014, 21(1): 92-104.   doi: 10.11748/bjmy.issn.1006-1703.2014.01.030
Jiang NY, Lin YS, Guan HX, et al.  131I guidelines for treating Graves' disease(2013 edition)[J]. Labeled Immun Clin Med, 2014, 21(1): 92-104.   doi: 10.11748/bjmy.issn.1006-1703.2014.01.030
[2] Wémeau JL, Klein M, Sadoul JL, et al.  Graves' disease: introduction, epidemiology, endogenous and environmental pathogenic factors[J]. Ann Endocrinol (Paris), 2018, 79(6): 599-607.   doi: 10.1016/j.ando.2018.09.002
[3] Smith TJ, Hegedüs L.  Graves' disease[J]. N Engl J Med, 2016, 375(16): 1552-1565.   doi: 10.1056/NEJMra1510030
[4] 祝林, 冯雪凤, 邵飞, 等.  放射性碘治疗497例格雷夫斯病的疗效及影响因素分析[J]. 重庆医科大学学报, 2018, 43(12): 1566-1571.   doi: 10.13406/j.cnki.cyxb.001862
Zhu L, Feng XF, Shao F, et al.  Efficacy of radioiodine therapy in treatment of Graves' disease and its influencing factors: an analysis of 497 cases[J]. J Chongqing Med Univ, 2018, 43(12): 1566-1571.   doi: 10.13406/j.cnki.cyxb.001862
[5] Chen DY, Schneider PF, Zhang XS, et al.  Striving for euthyroidism in radioiodine therapy of Graves' disease: a 12-year prospective, randomized, open-label blinded end point study[J]. Thyroid, 2011, 21(6): 647-654.   doi: 10.1089/thy.2010.0348
[6] Ross DS, Burch HB, Cooper DS, et al.  2016 American Thyroid Association Guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis[J]. Thyroid, 2016, 26(10): 1343-1421.   doi: 10.1089/thy.2016.0229
[7] 马玉波, 潘懿范, 杨丽雯.  依据甲状腺99TcmO4−显像ROI比值计算131I活度用于治疗Graves病[J]. 标记免疫分析与临床, 2019, 26(6): 939-944.   doi: 10.11748/bjmy.issn.1006-1703.2019.06.010
Ma YB, Pan YF, Yang LW.  The calculation of the dose of 131I-treatment in patients with Graves' disease based on thyroid scan's ROI ratio[J]. Labeled Immun Clin Med, 2019, 26(6): 939-944.   doi: 10.11748/bjmy.issn.1006-1703.2019.06.010
[8] Marinelli LD, Quimby EH, Hine GJ.  Dosage determination with radioactive isotopes[J]. Nucleonics, 1948, 2(4): 56-.
[9] Hyer SL, Pratt B, Gray M, et al.  Dosimetry-based treatment for Graves' disease[J]. Nucl Med Commun, 2018, 39(6): 486-492.   doi: 10.1097/MNM.0000000000000826
[10] Howarth D, Epstein M, Lan L, et al.  Determination of the optimal minimum radioiodine dose in patients with Graves' disease: a clinical outcome study[J]. Eur J Nucl Med, 2001, 28(10): 1489-1495.   doi: 10.1007/s002590100621
[11] Soli IA, Issoufou DM, Rahabi S, et al.  Determination of administered activities for the treatment of Graves' disease with iodine-131: proposition of a simplified dosimetric procedure[J]. World J Nucl Med, 2021, 20(3): 222-227.   doi: 10.4103/wjnm.WJNM_47_20
[12]

Hammes J, Van Heek L, Hohberg M, et al. Impact of different approaches to calculation of treatment activities on achieved doses in radioiodine therapy of benign thyroid diseases[J/OL]. EJNMMI Phys, 2018, 5(1): 32[2020-11-11]. https://ejnmmiphys.springeropen.com/articles/10.1186/s40658-018-0231-x. DOI: 10.1186/s40658-018-0231-x.
[13] 王任飞, 谭建, 张桂芝, 等.  131I治疗对Graves眼病转归的影响[J]. 国际放射医学核医学杂志, 2011, 35(4): 223-227.
Wang RF, Tan J, Zhang GZ, et al.  Effect of 131I therapy on outcomes of Graves' ophthalmopathy[J]. Int J Radiat Med Nucl Med, 2011, 35(4): 223-227.
[14] Wei Z, Tan J, Zhang GZ, et al.  Analysis of ¹³¹I therapy and correlation factors of Graves' disease patients: a 4-year retrospective study[J]. Nucl Med Commun, 2012, 33(1): 97-101.   doi: 10.1097/MNM.0b013e32834d3bb9
[15] Flower MA, al-Saadi A, Harmer CL, et al.  Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy[J]. Eur J Nucl Med, 1994, 21(6): 531-536.   doi: 10.1007/BF00173041
[16] Gosmann J, Willms D, Bell E, et al.  Improving treatment outcomes for Graves' disease patients with inactive forms of Graves' orbitopathy through an increased dose of radioiodine therapy[J]. Nuklearmedizin, 2020, 59(3): 260-268.   doi: 10.1055/a-1149-8552
[17] Willegaignon J, Sapienza MT, Buchpiguel CA.  Radioiodine therapy for Graves disease: thyroid absorbed dose of 300 Gy-tuning the target for therapy planning[J]. Clin Nucl Med, 2013, 38(4): 231-236.   doi: 10.1097/RLU.0b013e3182816717
[18] Willegaignon J, Sapienza MT, Coura-Filho GB, et al.  Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning[J]. Med Phys, 2014, 41(1): 012503-.   doi: 10.1118/1.4846056
[19] Schiavo M, Bagnara MC, Calamia I, et al.  A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves' disease: need to retarget the radiation committed dose to the thyroid[J]. J Endocrinol Invest, 2011, 34(3): 201-205.   doi: 10.1007/BF03347067
[20] Malapure SS, Mukherjee A, Bal C.  Radioiodine therapy of Graves' disease and the uptake paradox[J]. Indian J Nucl Med, 2020, 35(1): 17-20.   doi: 10.4103/ijnm.IJNM_158_19
[21] Traino AC, Di Martino F, Grosso M, et al.  A predictive mathematical model for the calculation of the final mass of Graves' disease thyroids treated with 131I[J]. Phys Med Biol, 2005, 50(9): 2181-2191.   doi: 10.1088/0031-9155/50/9/018
[22] Traino AC, Di Martino F, Grosso M, et al.  A study of the possibility of curing Graves' disease based on the desired reduction of thyroid mass (volume) as a consequence of 131I therapy: a speculative paper[J]. Nucl Med Commun, 2006, 27(5): 439-446.   doi: 10.1097/00006231-200605000-00005
[23] Aktaş GE, Turoğlu HT, Erdil TY, et al.  Long-term results of fixed high-dose I-131 treatment for toxic nodular goiter: higher euthyroidism rates in geriatric patients[J]. Mol Imaging Radionucl Ther, 2015, 24(3): 94-99.   doi: 10.4274/mirt.57060
[24] Jaiswal AK, Bal C, Damle NA, et al.  Comparison of clinical outcome after a fixed dose versus dosimetry-based radioiodine treatment of Graves' disease: results of a randomized controlled trial in Indian population[J]. Indian J Endocrinol Metab, 2014, 18(5): 648-654.   doi: 10.4103/2230-8210.139222
[25] Santos RB, Romaldini JH, Ward LS.  A randomized controlled trial to evaluate the effectiveness of 2 regimens of fixed iodine (131I) doses for Graves disease treatment[J]. Clin Nucl Med, 2012, 37(3): 241-244.   doi: 10.1097/RLU.0b013e31823ea6e0
[26] Bartalena L, Bogazzi F, Chiovato L, et al.  2018 European Thyroid Association (ETA) guidelines for the management of amiodarone-associated thyroid dysfunction[J]. Eur Thyroid J, 2018, 7(2): 55-66.   doi: 10.1159/000486957
[27] Sapienza MT, Coura-Filho GB, Willegaignon J, et al.  Clinical and dosimetric variables related to outcome after treatment of Graves' disease with 550 and 1110 MBq of 131I: results of a prospective randomized trial[J]. Clin Nucl Med, 2015, 40(9): 715-719.   doi: 10.1097/RLU.0000000000000840
[28] Bolch WE, Bouchet LG, Robertson JS, et al.  MIRD pamphlet No. 17: the dosimetry of nonuniform activity distributions-radionuclide S values at the voxel level. Medical Internal Radiation Dose Committee[J]. J Nucl Med, 1999, 40(1): 11S-36S.
[29] Riguetto CM, Miguel VP, João Pavin E, et al.  Fixed 30 mCi 131I-iodine therapy without recombinant human thyroid-stimulating hormone stimulation as an attractive therapeutic alternative in nontoxic nodular goiter[J]. Nucl Med Commun, 2020, 41(8): 727-732.   doi: 10.1097/MNM.0000000000001213
[30] Ariamanesh S, Ayati N, Mazloum Khorasani Z, et al.  Effect of different 131I dose strategies for treatment of hyperthyroidism on Graves' ophthalmopathy[J]. Clin Nucl Med, 2020, 45(7): 514-518.   doi: 10.1097/RLU.0000000000003086
[31] Wiersinga WM.  Graves' disease: can it be cured?[J]. Endocrinol Metab (Seoul), 2019, 34(1): 29-38.   doi: 10.3803/EnM.2019.34.1.29
[32] Lowdell CP, Spathis GS, Cosgrove DO, et al.  Low-dose 131I in treatment of Graves' disease[J]. J Roy Soc Med, 1985, 78(3): 197-202.   doi: 10.1177/014107688507800305
[33] 唐晓燕, 刘子太, 王羽, 等.  小剂量131碘分次疗法治疗Graves病327例疗效分析[J]. 中国地方病防治杂志, 2004, 19(2): 122-123.   doi: 10.3969/j.issn.1001-1889.2004.02.029
Tang XY, Liu ZT, Wang Y, et al.  Observation of therapeutic effect on 327 cases Graves' diseases with small dosage 131I[J]. Chin J Control Endemic Dis, 2004, 19(2): 122-123.   doi: 10.3969/j.issn.1001-1889.2004.02.029
[34]

Yu J, Tian AJ, Yuan X, et al. Subclinical hypothyroidism after 131I-treatment of Graves' disease: a risk factor for depression?[J/OL]. PLoS One, 2016, 11(5): e0154846[2020-11-11]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0154846. DOI: 10.1371/journal.pone.0154846.
[35] 王舰, 蔡海东, 吕明丽, 等.  131I固定计量法及计算计量法治疗甲亢的疗效评价[J]. 同济大学学报: 医学版, 2012, 33(1): 83-87, 93.   doi: 10.3969/j.issn1008-0392.2012.01.018
Wang J, Cai HD, Lyu ML, et al.  Comparison of fixed dose with calculated dose method of 131I treatment for Graves' hyperthyroidism[J]. J Tongji Univ (Med Sci), 2012, 33(1): 83-87, 93.   doi: 10.3969/j.issn1008-0392.2012.01.018
[36] Pardo FJP, Serrano RL, Cases FJG, et al.  A prospective comparative study of two methods of individual calculation of 131I activity in the treatment of hyperthyroidism[J]. Endocrinol Diabetes Nutr, 2020, 67(9): 568-577.   doi: 10.1016/j.endinu.2020.02.009
[37] Haase A, Bähre M, Lauer I, et al.  Radioiodine therapy in Graves' hyperthyroidism: determination of individual optimum target dose[J]. Exp Clin Endocrinol Diabetes, 2000, 108(2): 133-137.   doi: 10.1055/s-2000-5807
[38] Xing YZ, Zhang K, Jin G.  Predictive factors for the outcomes of Graves' disease patients with radioactive iodine (131I) treatment[J]. Biosci Rep, 2020, 40(1): BSR20191609-.   doi: 10.1042/BSR20191609
[39] Yang DR, Xue JJ, Ma WX, et al.  Prognostic factor analysis in 325 patients with Graves' disease treated with radioiodine therapy[J]. Nucl Med Commun, 2018, 39(1): 16-21.   doi: 10.1097/MNM.0000000000000770
[40] 郭坤, 高蕊, 于燕, 等.  表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J]. 国际放射医学核医学杂志, 2015, 39(1): 4-8.   doi: 10.3760/cma.j.issn.1673-4114.2015.01.003
Guo K, Gao R, Yu Y, et al.  The relationship between epidermal growth factor receptor mRNA expression and the efficacy of 131I treatment in hyperthyroidism patients[J]. Int J Radiat Med Nucl Med, 2015, 39(1): 4-8.   doi: 10.3760/cma.j.issn.1673-4114.2015.01.003
[41]

Hu RT, Liu DS, Li B. Predictive factors for early hypothyroidism following the radioactive iodine therapy in Graves' disease patients[J/OL]. BMC Endocr Disord, 2020, 20(1): 76[2020-11-11]. https://bmcendocrdisord.biomedcentral.com/articles/10.1186/s12902-020-00557-w. DOI: 10.1186/s12902-020-00557-w.